Thought Leadership
Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 102 posts
September 17, 2020 | Blog
Hitting the Mark: Lessons Learned From Blockbuster Drugs That Missed or Exceeded Analyst Expectations
Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.
September 8, 2020 | Blog
How Do Companies Spend the Revenue Generated from Blockbuster Drugs? A Closer Look at Vertex and Gilead
Blockbuster drugs can generate billions of dollars for pharmaceutical manufacturers, but what can be learned from the investment strategies that GILEAD and VERTEX pursued from the revenue that they generated from SOVALDI and ORKAMBI respectively?
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: Comparison of Healthcare Systems and Opportunities for Innovative Drugs Across India, Vietnam, and Indonesia
A research poster that aims to understand how various healthcare system archetypes in APAC markets (e.g., India, Vietnam, and Indonesia) lead to access for high-cost innovative oncology treatments.
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: Dancing with the Dragon – Considerations and Learnings in the 2019 China NRDL Negotiations
A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy
A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.